Efficacy and Safety of MP-424, Interferon Beta (IFN Beta), and Ribavirin(RBV) in Treatment-Naïve or Having Received Interferon Based Therapy With Chronic Hepatitis C (CHC)

NCT01753570 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

74

Enrollment

INDUSTRY

Sponsor class

Conditions

Chronic Hepatitis C(CHC)

Interventions

DRUG: MP-424
DRUG: RBV(24 weeks)
DRUG: IFN beta(24 weeks)
DRUG: RBV(48 weeks)
DRUG: IFN beta(48 weeks)

Sponsor

Tanabe Pharma Corporation

Collaborators

[object Object]